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1. Introduction 
Glomerular filtration rate (GFR) is now widely accepted as the best indicator of renal 
function in the state of health and illness.1,2  Current clinical guidelines advocate its use in 
the staging of chronic kidney disease as well as in assessing the risk of kidney failure under 
acute clinical, physiological, and pathological conditions.3-6 Acute renal failure (ARF) is a 
major cause of complications in the post-surgical and post-intervention vascular and cardiac 
procedure patient populations. ARF is also a major public health issue because it may lead 
to chronic renal failure. Real-time, continuous monitoring of GFR in patients at the bedside 
is particularly important in the case of critically ill or injured patients, and those undergoing 
organ transplantation because most of these patients face the risk of multiple organ failure 
(MOF) resulting in death.7-10   MOF is a sequential failing of lung, liver, and kidneys and is 
incited by one or more severe causes such as acute lung injury (ALI), adult respiratory 
distress syndrome (ARDS), hypermetabolism, hypotension, persistent inflammation, or 
sepsis. The transition from early stages of trauma to clinical MOF is marked by the extent of 
liver and renal failure and a change in mortality risk from about 30% to about 50%.10 
Accurate determination of GFR is also necessary for monitoring patients undergoing cancer 
chemotherapy with nephrotoxic anticancer drugs,11 or those at risk for contrast media 
induced nephropathy (CIN).12  Finally, GFR measurement is also useful for patients with 
chronic illness such as diabetes, hypertension, obesity, hyperthyroidism, cystic fibrosis, etc. 
who are at risk for renal impairment.13-15 
2. Current GFR markers 
In order to assess the status and to follow the progress of renal disease, there is a need to 
develop a simple, accurate, and continuous method for the determination of renal function 
by non-invasive procedures. At present, endogenous serum creatinine (1) (Fig. 1) 
concentration measured at frequent intervals over a 24-hour period has been the most 
common method of assessing renal function despite the well known serious limitations.16-18  
The results from this analysis are frequently misleading since the value is affected by age, 
state of hydration, renal perfusion, muscle mass, dietary intake, and many other 
anthropometric and clinical variables. Theoretical methods for estimating GFR (eGFR)19-21 
from body cell mass and plasma creatinine concentration have also been developed, but 
these methods also rely on the above anthropomorphic variables. Moreover, creatinine is  
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Fig. 1. Structures of Currently Known Exogenous GFR Markers. 
partially cleared by tubular secretion along with glomerular filtration, and, as Diskin17 recently 
remarked, “Creatinine clearance is not and has never been synonymous with GFR, and all of 
the regression analysis will not make it so because the serum creatinine depends upon many 
factors other than filtration.” More recently, endogenous cystatin-C has been suggested as an 
improvement over creatinine,15,20 but this marker also suffers from the same limitations as 
creatinine, and thus it remains questionable whether it is really an improvement. 
In the past several decades, exogenous tracers such as inulin (2), iothalamate (3), iohexol 
(4), 99mTc-DTPA (diethylenetriaminepentaacetate) (5), and 51Cr-EDTA (ethylenediamine-
tetraacetate) (6) (Fig.1), have been developed to determine GFR, but all of them require 
either radiometric, HPLC (high performance liquid chromatography), or X-ray 
fluorescence methods for detection and quantification.22-29 Unfortunately, all of these 
markers suffer from various undesirable properties including the use of radioactivity, 
ionizing radiation, and the laborious ex-vivo handling of blood and urine samples, and 
the use of HPLC method that render them unsuitable for continuous monitoring of renal 
function in the clinical setting. Furthermore, inulin as well as other polysaccharides are 
polydisperse polymers, and availability of these substances in a reliable, uniform batches 
is a serious limiting factor for their use as GFR markers. Currently, iothalamate and 
iohexol are the accepted standard for the assessment of GFR. However, iothalmate 
requires the collection of blood samples and requires HPLC method, which is not well 
suited for continuous monitoring. Continuous monitoring of GFR has been accomplished 
via radiometric12 and magnetic resonance imaging30 techniques, but these are not suitable 
at  the bedside. Hence, the availability of an exogenous marker for the measurement of 
GFR under specific yet changing circumstances would represent a substantial 
improvement over any currently available or widely practiced method. Moreover, a 
method that depends solely on the renal elimination of an exogenous chemical entity 
would provide an absolute and continuous pharmacokinetic measurement requiring less 
subjective interpretation based upon age, muscle mass, blood pressure, etc. 
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3. Development of fluorescent tracer agents 
Accordingly, there has been some effort on developing exogenous GFR tracer agents that 
absorb and emit in the visible or near infrared (NIR) region, which includes small molecules 
as well as macromolecular bioconjugates such FITC (fluorescien isothicyanate)-inulin and 
FITC- and Texas Red-dextrans.31-37 The key requirements for an ideal fluorescent tracer 
agent are:  (a) must be excited at and emit in the visible region ( ≥ ~425 nm); (b) must be 
highly hydrophilic; (c) must be either neutral or anionic; (c) must have very low or no 
plasma protein binding; (d) must not be metabolized in vivo, and (e) must clear exclusively 
via glomerular filtration as demonstrated by equality of plasma clearance with and without 
a tubular secretion inhibitor such as probenecid.38 The selection of the lead clinical 
candidate(s) may be based on secondary considerations such as the ease of synthesis, lack of 
toxicity, and stability. The secondary screening criteria should further take into account the 
tissue optics properties and the degree of extracellular distribution of the fluorescent tracers. 
Volume of distribution is an important parameter in the assessment of hydration state of the 
patient, whereas the absorption/emission properties provide essential information for the 
design of the probe. 
This chapter focuses on the most recent development on luminescent tracers for GFR 
measurement. There are basically two principal pathways for the design of fluorescent 
tracers for GFR determination. The first method involves enhancing the fluorescence of 
known renal agents that are intrinsically poor emitters such as lanthanide metal complexes; 
and the second involves transforming highly fluorescent dyes (which are intrinsically 
lipophilic) into hydrophilic, anionic species to force them to clear via the kidneys.32 In the 
first approach, several europium-DTPA complexes endowed with various molecular 
‘antenna’ to induce ligand-to-metal fluorescence resonance energy transfer (FRET) were 
prepared and tested.32  Some of metal complexes (e.g. compound 7 exhibited high (c.a. 2000-
fold) enhancement of europium fluorescence and underwent clearance exclusively through 
the kidneys, but whether they cleared exclusively via glomerular filtration remains 
uncertain. Moreover, the excitation maxima of these complexes remained in the violet or 
UV-A region.  
 
Fig. 2. Eu-DTPA-Quinoline Complex. 
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Pyrazines (Fig. 3) are one the very few classes of photostable small molecules having highly 
desirable properties for various biomedical and non-medical optical applications.39-41  
Pyrazine derivatives 8 containing electron donating groups (EDG) in the 2,5 positions and 
electron withdrawing groups (EWG) in the 3,6 positions such as compounds 9-11 are shown 
to absorb and emit in the visible region with a large Stokes shift on the order of ~ 100 nm 
and with fluorescence quantum yields of about 0.4.39,40  For example, conversion of the 
carboxyl group in 8 to the secondary amide derivatives 9 produces a bathochromic (red) 
shift of about 40 nm, and alkylation of the amino group in 9 produces further red shift of 
about 40 nm. Thus, the pyrazine nucleus offers considerable opportunity to ‘tune’ the 
electronic properties by even simple modifications. Furthermore, the relative small size of 
pyrazine renders it an ideal scaffold to introduce hydrophilic substituents to bring about 
renal clearance. 
 
Fig. 3. Pyrazine Derivatives. 
Based on the structure and properties of known GFR tracer agents, and on the primary and 
secondary considerations stated earlier, the set of GFR tracer agents can be divided finto our 
categories as outlined in Table 1. The upper and lower quadrants address the tissue optics 
differences, and the left and right quadrants address volume of distribution (Vd) differences. 
(Vd) is important not only in affecting clearance rates, but also in the assessment of 
hydration state of a patient. Tissue optics parameters are important in instrument design in 
that the longer the wavelength of light, the deeper the penetration into the tissue. Recently, 
low and high molecular weight hydrophilic pyrazine derivatives 12-15 (Fig. 4) bearing 
neutral and anionic side chains such as alcohols, carboxylic acids, and polyethylene glycol 
(PEG) units were reported.41 The structures of the candidates from each of the four 
quadrants above are shown in Fig. 2. Unlike inulin, dextran, and other polymers, 
compounds 13 and 15 are monodisperse. The photophysical and biological properties of 
these compounds are given in Table 2. Both plasma protein binding and urinary clearance 
properties are superior to iothalamate, which is a currently used ‘gold standard’ for clinical 
GFR measurement. Furthermore, all four compounds displayed insignificant 
biodegradation.  
Volume of Distribution 
Tissue Optics 
Short Wavelength 
Low Molecular Weight 
Short Wavelength 
High Molecular Weight 
Long Wavelength 
Low Molecular Weight 
Long Wavelength 
High Molecular Weight 
Table 1. Design of Exogenous Fluorescent GFR Tracers. 
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Fig. 4. Hydrophilic Pyrazine Derivatives. 
 12 13 14 15 Iothalamate 
Absorption Maxima, (max, nm) 435 437 488 499 NA 
Emission Maxima, (max, nm) 557 558 597 604 NA 
Plasma Protein Binding (%) 0 0 0 3 10 
Plasma Clearance Half-Life (min) 29 25 20 19 32 
Injected Dose Recovered in Urine at 6 Hrs (%) 90 71 88 97 80 
Clearance – No probenecid (mL/min) 2.5 NA 3.0 3.1 2.5 
Clearance – Probenecid, 70 mg/kg (mL/min) 2.6 NA 2.4 3.3 2.2 
Table 2. Physicochemical and Pharmacokinetic Properties of Pyrazine Tracers. 
An in vivo fluorescence image of the renal clearance of compound 13 is shown in Fig. 5. The 
panel contains images of three mice. The mouse in the middle was administered 300 L of a 
2 mM solution in phosphate-buffered saline (PBS) of compound 13. The other mice served 
as controls where the mice received only PBS. Compound 13 distributed throughout the 
body and then concentrated in one spot in the abdomen. Surgery after the 60 minute time 
point verified that this highly fluorescent spot in the abdomen was the bladder. Thus, this 
observation of fluorescence only appearing at the bladder is a visual demonstration of the 
high percent of injected dose recovered in urine given in Table 2. 
4. Real-time monitoring of renal clearance 
In vivo noninvasive real-time monitoring of renal clearance, with eventual translation to 
commercial development, has been demonstrated in the rodent model. A schematic of an 
apparatus is shown in Fig. 6. A 445 nm solid state laser was directed into one leg of a silica  
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Fig. 5. Optical Image of Pyrazine 13 at 1 Hour Post Administration. 
 
Fig. 6. Apparatus for non-invasive in vivo detection of fluorescence. 
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bifurcated fiber optic bundle, with the common end of this bifurcated bundle placed 
approximately 2 mm from the rat ear. The second leg of the bifurcated fiber optic bundle 
was fitted with a collimating beam probe. A long pass filter and narrow band interference 
filter were placed in front of a photosensor module. A chopper was placed after the laser 
and before the launch into the bifurcated cable. The output of the photosensor was 
connected to a lock-in amplifier. The lock-in output was digitized and the digitized data was 
acquired by computer using data acquisition software. 
Anesthesized Sprague-Dawley rats of weight ~ 400 g were used. A volume of 1 mL of a 0.4 
mg/mL concentration in PBS of compound 12 was administered to a rat with normal 
functioning kidneys and to a rat with a recent bi-lateral nephrectomy. The continuously 
monitored fluorescent signal is shown in Figure 5. An increase in fluorescence at the ear is 
immediately seen in both rats. In the normal rat, the fluorescence decreases back to baseline as 
the kidney removes compound 12 from the body. In the ligated rat, the fluorescence remains 
elevated with time as the body is unable to remove compound with the kidneys not functioning. 
 
Fig. 7. Continuous Monitoring of Pyrazine 12 in Normal and Partially Nephrectomized Rats. 
5. Conclusions 
On the basis of the fluorescence properties, plasma protein binding data, the injected dose 
recovered in urine, the plasma clearance data, and the renal tubular secretion studies, the 
pyrazine deriviatives 12-15 are promising candidates as exogenous fluorescent tracer agents 
for the determination of GFR under both chronic and acute settings. In the rat model, these 
compounds display superior properties compared to iothalamate, which is currently an 
accepted standard for the measurement of GFR.  
A prototype instrument for clinical trials has been developed based on the apparatus in 
Figure 4. A clinical trial with one of the pyrazine compounds is currently being planned. 
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The clinical trial will test the safety and efficacy of the tracer agent, as well as refine the 
instrumentation. Optimization parameters for the instrument include incident light power 
and power density, light delivery and collection fiber optics, light source and detector, 
placement of detector on body, and the data acquisition and analysis algorithm. 
The addition of a fluorescent GFR tracer agent would be a major addition to the armament 
of fluorescent compounds in clinical use today. Indocyanine green (ICG) is FDA-approved 
for use in angiography, cardiac output, and liver function.42 Currently, there are on-going 
clinical trials for lymph node mapping and melanoma imaging using ICG.43 Fluorescein is 
the only other FDA appoved fluorescent agent, used for angiography.42  A near-infrared dye 
for attachment to targeting vectors for optical imaging has been studied for safety and 
pharmacology, and may soon be ready for human clinical trials too.44 
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